Free-water imaging of the hippocampus is a sensitive marker of Alzheimer's disease

for the Alzheimer's Disease Neuroimaging Initiative

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Validating sensitive markers of hippocampal degeneration is fundamental for understanding neurodegenerative conditions such as Alzheimer's disease. In this paper, we test the hypothesis that free-water in the hippocampus will be more sensitive to early stages of cognitive decline than hippocampal volume, and that free-water in hippocampus will increase across distinct clinical stages of Alzheimer's disease. We examined two separate cohorts (N = 126; N = 112) of cognitively normal controls, early and late mild cognitive impairment (MCI), and Alzheimer's disease. Demographic, clinical, diffusion-weighted and T1-weighted imaging, and positron emission tomography (PET) imaging were assessed. Results indicated elevated hippocampal free-water in early MCI individuals compared to controls across both cohorts. In contrast, there was no difference in volume of these regions between controls and early MCI. ADNI free-water values in the hippocampus was associated with low CSF AB1–42 levels and high global amyloid PET values. Free-water imaging of the hippocampus can serve as an early stage marker for AD and provides a complementary measure of AD neurodegeneration using non-invasive imaging.

Original languageEnglish (US)
Article number101985
JournalNeuroImage: Clinical
Volume24
DOIs
StatePublished - 2019

Fingerprint

Hippocampus
Alzheimer Disease
Water
Positron-Emission Tomography
Amyloid
Demography
Cognitive Dysfunction

Keywords

  • Free-water imaging
  • Hippocampus
  • Mild cognitive impairment
  • Neurodegeneration

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Neurology
  • Clinical Neurology
  • Cognitive Neuroscience

Cite this

Free-water imaging of the hippocampus is a sensitive marker of Alzheimer's disease. / for the Alzheimer's Disease Neuroimaging Initiative.

In: NeuroImage: Clinical, Vol. 24, 101985, 2019.

Research output: Contribution to journalArticle

for the Alzheimer's Disease Neuroimaging Initiative. / Free-water imaging of the hippocampus is a sensitive marker of Alzheimer's disease. In: NeuroImage: Clinical. 2019 ; Vol. 24.
@article{d7576f17fb164c45ab5efeac455b032a,
title = "Free-water imaging of the hippocampus is a sensitive marker of Alzheimer's disease",
abstract = "Validating sensitive markers of hippocampal degeneration is fundamental for understanding neurodegenerative conditions such as Alzheimer's disease. In this paper, we test the hypothesis that free-water in the hippocampus will be more sensitive to early stages of cognitive decline than hippocampal volume, and that free-water in hippocampus will increase across distinct clinical stages of Alzheimer's disease. We examined two separate cohorts (N = 126; N = 112) of cognitively normal controls, early and late mild cognitive impairment (MCI), and Alzheimer's disease. Demographic, clinical, diffusion-weighted and T1-weighted imaging, and positron emission tomography (PET) imaging were assessed. Results indicated elevated hippocampal free-water in early MCI individuals compared to controls across both cohorts. In contrast, there was no difference in volume of these regions between controls and early MCI. ADNI free-water values in the hippocampus was associated with low CSF AB1–42 levels and high global amyloid PET values. Free-water imaging of the hippocampus can serve as an early stage marker for AD and provides a complementary measure of AD neurodegeneration using non-invasive imaging.",
keywords = "Free-water imaging, Hippocampus, Mild cognitive impairment, Neurodegeneration",
author = "{for the Alzheimer's Disease Neuroimaging Initiative} and Edward Ofori and DeKosky, {Steven T.} and Marcelo Febo and Luis Colon-Perez and Paramita Chakrabarty and Ranjan Duara and Malek Adjouadi and Golde, {Todd E.} and Vaillancourt, {David E.}",
year = "2019",
doi = "10.1016/j.nicl.2019.101985",
language = "English (US)",
volume = "24",
journal = "NeuroImage: Clinical",
issn = "2213-1582",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Free-water imaging of the hippocampus is a sensitive marker of Alzheimer's disease

AU - for the Alzheimer's Disease Neuroimaging Initiative

AU - Ofori, Edward

AU - DeKosky, Steven T.

AU - Febo, Marcelo

AU - Colon-Perez, Luis

AU - Chakrabarty, Paramita

AU - Duara, Ranjan

AU - Adjouadi, Malek

AU - Golde, Todd E.

AU - Vaillancourt, David E.

PY - 2019

Y1 - 2019

N2 - Validating sensitive markers of hippocampal degeneration is fundamental for understanding neurodegenerative conditions such as Alzheimer's disease. In this paper, we test the hypothesis that free-water in the hippocampus will be more sensitive to early stages of cognitive decline than hippocampal volume, and that free-water in hippocampus will increase across distinct clinical stages of Alzheimer's disease. We examined two separate cohorts (N = 126; N = 112) of cognitively normal controls, early and late mild cognitive impairment (MCI), and Alzheimer's disease. Demographic, clinical, diffusion-weighted and T1-weighted imaging, and positron emission tomography (PET) imaging were assessed. Results indicated elevated hippocampal free-water in early MCI individuals compared to controls across both cohorts. In contrast, there was no difference in volume of these regions between controls and early MCI. ADNI free-water values in the hippocampus was associated with low CSF AB1–42 levels and high global amyloid PET values. Free-water imaging of the hippocampus can serve as an early stage marker for AD and provides a complementary measure of AD neurodegeneration using non-invasive imaging.

AB - Validating sensitive markers of hippocampal degeneration is fundamental for understanding neurodegenerative conditions such as Alzheimer's disease. In this paper, we test the hypothesis that free-water in the hippocampus will be more sensitive to early stages of cognitive decline than hippocampal volume, and that free-water in hippocampus will increase across distinct clinical stages of Alzheimer's disease. We examined two separate cohorts (N = 126; N = 112) of cognitively normal controls, early and late mild cognitive impairment (MCI), and Alzheimer's disease. Demographic, clinical, diffusion-weighted and T1-weighted imaging, and positron emission tomography (PET) imaging were assessed. Results indicated elevated hippocampal free-water in early MCI individuals compared to controls across both cohorts. In contrast, there was no difference in volume of these regions between controls and early MCI. ADNI free-water values in the hippocampus was associated with low CSF AB1–42 levels and high global amyloid PET values. Free-water imaging of the hippocampus can serve as an early stage marker for AD and provides a complementary measure of AD neurodegeneration using non-invasive imaging.

KW - Free-water imaging

KW - Hippocampus

KW - Mild cognitive impairment

KW - Neurodegeneration

UR - http://www.scopus.com/inward/record.url?scp=85071395246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071395246&partnerID=8YFLogxK

U2 - 10.1016/j.nicl.2019.101985

DO - 10.1016/j.nicl.2019.101985

M3 - Article

C2 - 31470214

AN - SCOPUS:85071395246

VL - 24

JO - NeuroImage: Clinical

JF - NeuroImage: Clinical

SN - 2213-1582

M1 - 101985

ER -